Cell MedX Corp. Engages Dr. Peter Eppinga as Lead Investigator in the eBalance(R) R&D Experience Study

Carson City, Nevada--(Newsfile Corp. - December 12, 2019) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has recruited Dr. Peter Eppinga, a family practice physician (MD, CCFP) licensed in the province of British Columbia, Canada, as the lead investigator in the eBalance^® R&D Experience Study (the "Study"). For additional information please refer to the news release the Company disseminated on August 19, 2019.

The Company received very encouraging results from an observational clinical trial (the "Trial") carried out by Dr. Richard Tytus and his team at the Hamilton Research Group in Hamilton, Ontario. Nutrasource Diagnostics Inc., a contract research organization, completed the final report on the Trial. The objective of this Trial was to assess the eBalance therapy as an adjunct treatment for diabetes and related complications in Type 1 and Type 2 diabetics over a three-month period. For additional information please see news releases dated January 24, 2018 and January 30, 2018.

Due to the positive results of the Trial, the Company has decided to conduct a further third-party observational study. The primary objective of the Study is to receive feedback from individuals who have been using the eBalance^® for over a year to gain feedback regarding their well-being.

While the eBalance device is currently designed as a wellness device, individuals have reported health benefits they directly attribute to their use of the eBalance^® including improved management of their diabetes, hypertension and chronic pain.

Specifically, individuals with Type 1 and Type 2 diabetes have reported stabilization of their blood glucose after using the eBalance^® device, providing them with a greater ability to manage their symptoms.

An individual who has been managing Type 1 diabetes for more than 50 years, reported a drop in HbA1c from 8.5% down to 6.8%, an impressive 20% decrease which brought their three-month average blood glucose into a safe range and within Canadian Diabetes Targets. The individual also reported being able to manage daily blood glucose levels much easier when using the device. They report that their pre-lunch daily blood glucose readings ranged from 10.1-6.5mmol/L prior to using the device and lowered to 5.9-6.6mmol/L pre-meal on average, well into the safe target range.

Diabetes Canada recommends a patient with Type 1 or Type 2 diabetes aim for an HbA1c of 7% (https://guidelines.diabetes.ca/reduce-complications/a1ctarget).

The current Study is also designed to further confirm safety, as reported in the previous Trial, with a secondary objective of looking at baseline chronic care and complex care biometrics that warrant additional investigation in a clinical family practice setting.

About Cell MedX Corp.

Cell MedX Corp. is an early development stage biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, and high blood pressure. For more information about the Company and its technology please visit the Company's website at www.cellmedx.com/investors/overview/. For the Company's newsletter please visit www.cellmedx.com/media/newsletters/.

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
CEO, Director

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, and Annual Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

The information presented in this press release, including the statements made regarding the eBalance® device, have not been evaluated by the Food and Drug Administration or Health Canada, nor has it been peer reviewed. eBalance® should not be viewed as a substitute for professional medical advice, diagnosis, or treatment. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

SOURCE:
Cell MedX Corp.
For further information please visit: www.cellmedx.com
Toll free: 1.844.238.2692

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/50740